Degarelix: A new approach for the treatment of prostate cancer

Neuroendocrinology

Volumn 90, Issue 3, 2009, Pages 235-244

  Persson, Bo Eric ^a,b,d   Kold Olesen, Tine ^c   Jensen, Jens Kristian ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

^b Elisabethsjukhuset   (Sweden)

^c Ferring Pharmaceuticals Inc USA   (United States)

^d International Center   (Switzerland)

Author keywords

Degarelix; Gonadotrophin releasing hormone receptor blocker; Hormonal therapy; Prostate cancer

Indexed keywords

ANDROSTANOLONE; DEGARELIX; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BONE PAIN; CHILL; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INJECTION SITE PAIN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; URINARY TRACT INFECTION; URINE RETENTION; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; TREATMENT OUTCOME;

EID: 70350257619     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228832     Document Type: Article

References (31)

1. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-508.
2. Lin BJ, Chen KK, Chen MT, Chang LS: The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 1994; 43: 834-837.
3. Oefelein MG, Cornum R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-729.
4. Rohl HF, Beuke HP: Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992; 26: 11-14.
5. Conn PM, Crowley WF Jr: Gonadotropin-releasing hormone and its analogs. Ann Rev Med 1994; 45: 391-405.
6. Huirne JA, Lambalk CB: Gonadotropin-releasing- hormone-receptor antagonists. Lancet 2001; 358: 1793-1803.
7. Sasagawa I, Kubota Y, Nakada T, Suzuki H, Hirano J, Sugano O, Kato H, Imamura A, Matsushita K, Onmura Y, Saito M, Adachi M: Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate. Int Urol Nephrol 1998; 30: 745-753.
8. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-1589.
9. Zinner NR, Bidair M, Centeno A, Tomera K: Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004; 64: 1177-1181.
10. Heidenreich H, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, Schmid HP, Zattoni F: Guidelines on prostate cancer. European Association of Urology 2007. http://www. uroweb.org/fileadmin/user-upload/Guidelines/ 07-Prostate-Cancer- 2007.pdf, accessed 24 February 2009.
11. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JA Jr, Bennett CL, Scher HI: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22: 2927-2941.
12. AstraZeneca: Zoladex - (goserelin acetate) prescribing information, November 2008. http://www.astrazeneca-us.com/pi/zoladex3-6.pdf, accessed 24 February 2009.
13. Bubley GJ: Is the flare phenomenon clinically significant? Urology 2001; 58(suppl 1): 5-9.
14. Takeda: Lupron 11.25 mg summary of product characteristics, 2005. http://www.rxlist. com/lupron-depot-1125-drug.htm, accessed 27 January 2009.
15. McLeod DG: Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.
16. Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, Chang GC, Wolkov HB, Gilbert RM: Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996; 199: 451-455.
17. Broqua P, Riviere PJM, Conn PM, Rivier JE, Aubert ML, Junien JL: Pharmacological profile of a new, potent, and long-acting gonadotropin- releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002; 301: 95-102.
18. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE: GnRH antagonists: a new generation of long acting analogues incorporating p-ureidophenylalanines at positions 5 and 6. J Med Chem 2001; 44: 453-467.
19. Koechling W: Effect of various GnRH antagonists on histamine release from human skin. 8th Int Symp GnRH Analogues Cancer Hum Reprod, Salzburg, February 2005.
20. Schwach G, Oudry N, Delhomme S, Luck M, Lindner H, Gurny R: Biodegradable microparticles for sustained release of a new GnRH antagonist. I. Screening commercial PLGA and formulation technologies. Eur J Pharm Biopharm 2003; 56: 327-336.
21. Schwach G, Oudry N, Giliberto JP, Broqua P, Luck M, Lindner H, Gurny R: Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist. II. In vivo performance. Eur J Pharm Biopharm 2004; 57: 441-446
22. Balchen T, Agerso H, Olesen TK, Jensen JK, Senderovitz T: Pharmacokinetics, pharmacodynamics, and safety of a novel fast-acting gonadotropin-releasing hormone receptor blocker, degarelix, in healthy men. 8th Int Symp GnRH Analogues Cancer Hum Reprod, Salzburg, February 2005.
23. Weston P, Hammonds J, Vaughton K, Olesen TK, Jensen JK, Eskerod O, Persson BE: Degarelix: a novel GnRH antagonist tested in a multicenter, randomized dose-finding study in prostate cancer patients. BJU Int 2004; 94(suppl 2):57-58.
24. Tammela TLJ, Iversen P, Johansson JE, Persson BE, Jensen JK, Olesen TK: Degarelix - a phase II multicenter, randomized dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients (abstract 904). Eur Urol Suppl 2005; 4: 243.
25. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Olesen TK; on behalf of the Degarelix Study Group: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1- yr, multicentre, randomised, phase II dosefinding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805-815.
26. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; on behalf of the Degarelix Study Group: A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-1992.
27. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008; 102: 1531-1538.
28. Boccon-Gibod L, Klotz L, Schroder FH, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK: Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomized, open-label, parallel-group phase III study in prostate cancer patients (abstract 537). Eur Urol Suppl 2005; 7: 205.
29. Oka D, Shiba M, Arai Y, Nakayama M, Takayama H, Inoue H, Nishimura K, Nonomura M, Okuyama A: Skin reactions to 3- month depot-type of luteinizing hormonereleasing hormone agonist therapy. JMAJ 2006; 49: 48-54.
30. Sanofi-Aventis: Eligard 7.5 mg US prescribing information, February 2008. http://products. sanofi-aventis.us/eligard/eligard-75. html, accessed 24 February 2009.
31. Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M: An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003; 62: 877-882.